This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
ThousandOaks-based biotech giant Amgen has backed a developer of therapeutic antibodies, via its venture capital arm, Amgen Ventures. Other investors in the round were ARCH Venture Partners, Canaan Partners, MPM Capital, Healthcare Ventures, Alexandria Real Estate Equities, and Zenyaku Kogyo. READ MORE>>.
ThousandOaks-based Ceres , a developer of biofuel crop technology, has raised another $20M in funding, according to a regulatory filing from the firm Friday. Ceres has previously raised funds from Warburg Pincus, Soros Private Equity, QuestMark Partners, Oxford BioScience, Oppenheimer, Monsanto, KBC, H&Q, and GIMV.
ThousandOaks-based biotech giant Amgen is a target of activist investor group Third Point , urging the company yesterday to split the company in two. amgen third point activist investors merger acquisition split private equity thirdpoint' READ MORE>>.
ThousandOaks-based ImmunGene , a startup biotech company developing antibody-based, protein therapeutics for treating cancer, said today that it has raised $9M in a Series A funding, to advance its early stage development products. According to the company, the funding came from Ally Bridge Group. The startup is led by Sanjay D.
ThousandOaks-based Ceres , a developer of biofuel crop technology, and Novozymes , a developer of enzymes, said today that the two have entered into a research collaboration around cellulosic biofuel production. Ceres is working on both crops to optimize the amount of sugar which can be used to produce biofuel. READ MORE>>.
Los Angeles-based Internet Brands , which operates a suite of online, advertising driven websites across a wide range of verticals, said Monday that it would go private in a $640M, private equity deal, bucking the trend of Southern California companies filing to get to the public markets. Internet Brands had gone public just three years ago.
ThousandOaks-based Amgen announced on Thursday that it has added Fred Hassan, Partner and Managing Director at private equity investor Warburg Pincus, to its board. Hassan also was Chairman of the Board and CEO of Schering-Plough Corporation, and had served at Pharmacia Corporation, Ubjohn, Wyeth, and Sandoz Pharmaceuticals.
ThousandOaks-based SunBrite TV , a manufacturer of large screen, HDTV screens specifically designed to be installed outdoors, next to pools, on patios, and elsewhere, has been acquired by SnapAV , which is owned by private equity investor General Atlantic. Financial terms of the acquisition were not disclosed.
ThousandOaks-based wireless networking equipment maker Xirrus has been acquired by Riverbed , to help bolster its SD WAN efforts, the two said on Wednesday. Financial terms of the acquisition were not announced. Riverbed said it will continue to offer up Xirrus as a stand-alone enterprise WLAN solution.
The firm, which is based in Northern California but has major operations in ThousandOaks, said that Elevation will continue to hold $50M in Series B preferred stock in the firm. Move, Inc. , Move said the moves are part of a plan to "streamline" its capital structure.
ThousandOaks-based biotech giant Amgen said today that its CFO, David W. Meline, is planning to retire, serving as CFO through the end of 2019, but will remain at the company through the second quarter of 2020. Meline--who has been Executive Vice President and Chief Financial Officer at Amgen since 2014--will be replaced by Peter H.
I grew up in ThousandOaks, went to USC, and we met each other way back in the 90's. Where there are lots of players focused on different types of equity, different types of investments, different types of debt, they're doing it in a very unfocused manner. Brew Johnson: It's exciting to be building this business in LA.
It’s the first partnership for Jounce, and a big one: the startup got a $225 million up front cash payment from Celgene and a $36 million equity investment. And in other Amgen news, the ThousandOaks, CA, company filed for FDA approval of osteoporosis drug romosuzumab.
Kobe Bryant , the basketball legend who also was one half of Los Angeles private equity investment firm Bryant Stibel , is dead at the age of 41, after a tragic helicopter crash in Calabasas took his life, the life of one of his daughters, and seven others.
—On the positive side, ThousandOaks, CA-based Amgen (NASDAQ: AMGN ) released an overview of Phase 2 data that showed its migraine prevention drug, erenumab, is keeping pace with rival drugs in a heated race to market.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content